Pair Name	Berberine, Niraparib
Disease Info	[ICD-11: 2C73]	Ovarian cancer		Investigative
Biological Phenomena	Induction-->DNA damage
Gene Regulation	Down-regulation	Expression	RAD51	hsa5888
	Down-regulation	Expression	NR1H4	KEGG ID N.A.
	Up-regulation	Phosphorylation	H2AX	hsa3014
In Vitro Model	A2780	Ovarian endometrioid adenocarcinoma	Homo sapiens (Human)	CVCL_0134
	HO-8910	Human papillomavirus-related cervical adenocarcinoma	Homo sapiens (Human)	CVCL_6868
In Vivo Model	The animals were subcutaneously inoculated with 1 × 106 A2780 cells (suspended in 100 μl PBS) and six days later the tumor-bearing mice were randomly divided into four groups and were then treated daily by oral gavage with vehicle (sodium carboxymethycellulose, SCMC), berberine (200 mg/kg bodyweight), niraparib (40 mg/kg bodyweight) and berberine (200 mg/kg) in combination with niraparib (40 mg/kg), respectively, for 15 days.
Result	The results indicate that by inducing oxidative DNA damage and downregulating HRR in cancer cells berberine is able to further sensitize cancer cells to PARP inhibition. These results demonstrate a potential therapeutic value of combined application of berberine and PARP inhibitors in ovarian cancer treatment.